IL-6 and IL-8 responses of colorectal cancer in vivo and in vitro cancer cells subjected to simvastatin

Journal of Physiology and Pharmacology

Volumn 60, Issue 4, 2009, Pages 141-146

  Malicki, S ^a   Winiarski, M ^b   Matlok, M ^b   Kostarczyk, W ^b   Guzdek, A ^a   Konturek, P C ^c  

^a JAGIELLONIAN UNIVERSITY   (Poland)

^b JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^c UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

Caco 2 cells; Colorectal cancer; IL 6; IL 8; Statins; Tumor; Tumor necrosis factor alpha

Indexed keywords

INTERLEUKIN 6; INTERLEUKIN 8; MESSENGER RNA; SIMVASTATIN;

ARTICLE; CANCER CELL; CELL STRAIN CACO 2; COLORECTAL CANCER; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFECT; DRUG INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

CACO-2 CELLS; COLORECTAL NEOPLASMS; HT29 CELLS; HUMANS; INTERLEUKIN-6; INTERLEUKIN-8; INTESTINAL MUCOSA; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SIMVASTATIN; TIME FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 75749125388     PISSN: 08675910     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Nicum S, Midgley R, Kerr DJ. Colorectal cancer. Acta Oncol 2003; 42(4): 263-275.
2. Naka T, Nishimoto N, Kishimoto T. The paradigm of IL-6: from basic science to medicine Arthritis Res 2002; 4: 233-242.
3. Galizia G, Orditura M, Romano C, et al. Prognostic significance of circulating IL-10 and IL-6 serum levels in colon cancer patients undergoing surgery. Clin Immunol 2002; 102: 169-178.
4. Chung YC, Chang YF. Serum interleukin-6 levels reflect the disease status of colorectal cancer. Surg Oncol 2003; 83: 222-226.
5. Kaminska J, Kowalska MM, Nowacki MP, Chwalinski MG, Rysinska M, Fuksiewicz M. CRP, TNFα, IL-6, IL-8 and IL-10 in blood serum of colorectal cancer patients. Pathol Oncol Res 2000; 6: 38-41.
6. Kinoshita T, Ito H, Miki C. Serum interleukin-6 level reflects the tumor proliferative activity in patients with colorectal carcinoma. Cancer 1999; 85: 2526-2531.
7. Belluco C, Nitti D, Frantz M, et al. Interleukin-6 blood level is associated with circulating carcinoembryonic antigen and prognosis in patients with colorectal cancer. Ann Surg Oncol 2000; 7: 133-138.
8. Nikiteas NI, Tzanakis N, Gazouli M, ET, et al. Serum IL-6, TNFalpha and CRP levels in Greek colorectal cancer patients: prognostic implications. World J Gastroenterol 2005; 11: 1639-1643.
9. Chung YC, Chaen YL, Hsu CP. Clinical significance of tissue expression of interleukin-6 in colorectal carcinoma. Anticancer Res 2006; 26: 3905-3911.
10. Kaminska J, Nowacki MP, Kowalska M, et al. Clinical significance of serum cytokine measurements in untreated colorectal cancer patients: soluble tumor necrosis factor receptor type I - an independent prognostic factor. Tumor Biol 2005; 26: 186-194.
11. Schneider MR, Hoeflich A, Fischer JR, Wolf E, Sordat B, Lahm H. Interleukin-6 stimulates clonogenic growth of primary and metastatic human colon carcinoma cells. Cancer Lett 2000; 151: 31-38.
12. Yuan H, Liddle FJ, Mahajan S, Frank DA. IL-6-induced survival of colorectal carcinoma cells is inhibited by butyrate through down-regulation of the IL-6 receptor. Carcinogenesis 2004; 25: 2247-255.
13. Rollwagen FM, Madhavan S, Singh A, Li YY, Wolcott K, Maheshwari R. IL-6 protects enterocytes from hypoxia-induced apoptosis by induction of bcl-2 mRNA and reduction of fas mRNA. Biochem Biophys Res Commun 2006; 347: 1094-1098.
14. Takeda A, Stoeltzing O, Ahmad SA, et al. Role of angiogenesis in the development and growth of liver metastasis. Ann Surg Oncol 2002; 9(7): 610-616.
15. Baggiolini M, Clark-Lewis I. Interleukin 8, a chemotactic and inflammatory cytokine. FEBS Lett 1992; 307: 97-101.
16. Konturek PC, Rembiasz K, Burnat G, et al. Effects of cyclooxygenase-2 inhibition on serum and tumor gastrins and expression of apoptosis-related proteins in colorectal cancer. Dig Dis Sci 2006; 51: 779-787.
17. Terada H, Urano T, Konno H. Association of interleukin-8 and plasminogen activator system in the progression of colorectal cancer. Eur Surg Res 2005; 37: 166-172.
18. Rubie C, Frick VO, Pfeil S, et al. Correlation of IL-8 with induction, progression and metastatic potential of colorectal cancer. World J Gastroenterol 2007; 13: 4996-5002.
19. Li A, Varney ML, Singh RK. Expression of interleukin 8 and its receptors in human colon carcinoma cells with different metastatic potentials. Clin Cancer Res 2001; 7: 3298-3304.
20. Kuilman T, Michaloglou C, Vredeveld LC, et al. Oncogeneinduced senescence relayed by an interleukin-dependent inflammatory network. Cell 2008; 133: 1019-1031.
21. Athyros VG, Kakafika AI, Tziomalos K, Karagiannis A, Mikhailidis DP. Pleiotropic effects of statins-clinical evidence. Curr Pharm Des 2009; 15(5): 479-489.
22. Li JJ, Chen XJ. Simvastatin inhibits interleukin-6 release in human monocytes stimulated by C-reactive protein and lipopolysaccharide. Coron Artery Dis 2003; 14: 329-334.
23. Panichi V, Paoletti S, Mantuano E, et al. In vivo and in vitro effects of simvastatin on inflammatory markers in pre-dialysis patients. Nephrol Dial Transplant 2006; 21:337-344.
24. Mantuano E, Santi S, Filippi C, et al. Simvastatin and fluvastatin reduce interleukin-6 and interleukin-8 lipopolysaccharide (LPS) stimulated production by isolated human monocytes from chronic kidney disease patients. Biomed Pharmacother 2007; 61: 360-365.
25. Sakoda K, Yamamoto M, Negishi Y, Liao JK, Node K, Izumi Y. Simvastatin decreases IL-6 and IL-8 production in epithelial cells. J Dent Res 2006; 85: 520-523.
26. Lazzerini PE, Lorenzini S, Selvi E, et al. Simvastatin inhibits cytokine production and nuclear factor-kB activation in interleukin 1beta-stimulated synoviocytes from rheumatoid arthritis patients. Clin Exp Rheumatol 2007; 25: 696-700.
27. Hindler K, Cleeland CS, Rivera E, Collard CD. The role of statins in cancer therapy. Oncologist 2006; 11(3): 306-315.
28. Konturek PC, Burnat G, Hahn EG. Inhibition of Barrett's adenocarcinoma cell growth by simvastatin: involvement of COX-2 and apoptosis-related proteins. J Physiol Pharmacol 2007; 58(Suppl. 3): 141-148.
29. Sassano A, Platanias LC. Statins in tumor suppression. Cancer Lett 2008; 260(1-2): 11-19.
30. Cichoz-Lach H, Celinski K. Modern methods of endoscopic diagnosis of gastrointestinal tract. J Physiol Pharmacol 2007; 58(Suppl. 3): 21-31.
31. Konturek PC, Burnat G, Brzozowski T, Zopf Y, Konturek SJ. Tryptophan free diet delays healing of chronic gastric ulcers in rat. J Physiol Pharmacol 2008; 59(Suppl. 2): 53-65.
32. Brozek W, Bises G, Fabjani G, Cross HS, Peterlik M. Clonespecific expression, transcriptional regulation, and action of interleukin-6 in human colon carcinoma cells. BMC Cancer 2008; 18; 8:13.
33. Becker C, Fantini MC, Schramm C, et al. TGF-beta suppresses tumor progression in colon cancer by inhibition of IL-6 trans-signaling. Immunity 2004; 21: 491-501.
34. Walia B, Wang L, Merlin D, Sitaraman SV. TGF-beta downregulates IL-6 signaling in intestinal epithelial cells: critical role of SMAD-2. FASEB J 2003; 17: 2130-2132.
35. Dixon DA, Tolley ND, King PH, et al. Altered expression of the mRNA stability factor HuR promotes cyclooxygenase-2 expression in colon cancer cells. J Clin Invest 2001; 108: 1657-1665.
36. Csiszar A, Szentes T, Haraszti B, Balazs A, Petranyi GG, Pocsik E. The pattern of cytokine gene expression in human colorectal carcinoma. Pathol Oncol Res 2004; 10: 109-116.
37. Poynter JN, Gruber SB, Higgins PD, et al. Statins and the risk of colorectal cancer. N Engl J Med 2005; 21: 2184-2192.
38. Siddiqui AA, Nazario H, Mahgoub A, Patel M, Cipher D, Spechler SJ. For patients with colorectal cancer, the long term use of statins is associated with better clinical outcomes. Dig Dis Sci 2009; 54: 1307-1311.
39. Hoffmeister M, Chang-Claude J, Brenner H. Individual and joint use of statins and low-dose aspirin and risk of colorectal cancer: a population-based case-control study. Int J Cancer 2007; 121: 1325-1330.
40. Bonovas S, Filioussi K, Flordellis CS, Sitaras NM. Statins and the risk of colorectal cancer: a meta-analysis of 18 studies involving more than 1.5 million patients. J Clin Oncol 2007; 25: 3462-3468